Skip to main content
K

KOREAN DRUG CO., LTD. — Investor Relations & Filings

Ticker · 014570 ISIN · KR7014570006 KO Manufacturing
Open in API
Filings indexed 203 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 014570

About KOREAN DRUG CO., LTD.

http://www.kdpharma.co.kr/

Korean Drug Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of healthcare products. The company's portfolio includes over-the-counter (OTC) and prescription (ETC) medicines, health supplements, cosmetics, and medical devices. It aims to provide comprehensive health solutions. The company is also active in research and development, maintaining a drug pipeline and conducting clinical trials in various therapeutic areas, including treatments for the nervous system.

Recent filings

Filing Released Lang Actions
소속부변경
Regulatory Filings
2026-04-30 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 1% confidence The document is titled “자기주식처분결과보고서” (Report on the results of disposal of treasury shares) and provides detailed information on the disposal of the company’s own shares (dates, quantities, prices, post-transaction holdings). This corresponds exactly to a transaction in own shares report.
2026-04-07 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 1% confidence The document is titled “주요사항보고서(자기주식 처분 결정)” and details the decision by the company’s board to dispose of treasury shares (자기주식) – including number of shares, price basis, disposal method, and relevant disclosures. This falls squarely under a report of the company transacting in its own shares (share repurchase/issuance). Therefore it is classified as Transaction in Own Shares (Code: POS).
2026-03-31 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 1% confidence The document is a 'Corporate Value Enhancement Plan' (기업가치 제고 계획) filed by Korea Pharma. It outlines future financial goals, dividend policies, and strategic initiatives. In the context of Korean regulatory filings (DART), this type of voluntary disclosure regarding corporate governance and value enhancement strategies is classified as a general regulatory filing, as it does not fit into specific categories like financial reports or audit reports.
2026-03-20 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과) for the company '고려제약'. It details the approval of financial statements, dividend resolutions, and the election of directors. This falls directly under the category of Declaration of Voting Results & Voting Rights Announcements.
2026-03-20 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 46th fiscal year (2025) of 'Korean Drug Co., Ltd.' (고려제약). It contains detailed company information, management details, capital changes, shareholding structure, and governance information. In the South Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the US 10-K annual report, as it is the comprehensive annual filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). FY 2025
2026-03-12 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.